Akari Therapeutics, PLC (AKTX)

NASDAQ: AKTX · IEX Real-Time Price · USD
0.567
-0.006 (-1.01%)
Nov 25, 2022 4:00 PM EDT - Market closed
-1.01%
Market Cap 32.86M
Revenue (ttm) n/a
Net Income (ttm) -18.10M
Shares Out 5.93B
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,084
Open 0.542
Previous Close 0.573
Day's Range 0.5 - 0.577
52-Week Range 0.381 - 1.7
Beta 1.28
Analysts Buy
Price Target n/a
Earnings Date Dec 7, 2022

About AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom. [Read more]

Industry Pharmaceuticals
CEO Gur Roshwalb
Employees 9
Stock Exchange NASDAQ
Ticker Symbol AKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...

3 days ago - GlobeNewsWire

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

NEW YORK and LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...

2 weeks ago - GlobeNewsWire

Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

NEW YORK and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...

2 weeks ago - GlobeNewsWire

Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Of...

NEW YORK and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...

2 weeks ago - GlobeNewsWire

Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference

NEW YORK and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...

3 weeks ago - GlobeNewsWire

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...

4 weeks ago - GlobeNewsWire

Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

NEW YORK and LONDON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases,...

1 month ago - GlobeNewsWire

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases,...

2 months ago - GlobeNewsWire

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases,...

2 months ago - GlobeNewsWire

Akari Therapeutics Narrows Pipeline Focus

NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...

3 months ago - GlobeNewsWire

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopa...

NEW YORK and LONDON, July 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory...

3 months ago - GlobeNewsWire

Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

NEW YORK and LONDON, July 20, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, ...

4 months ago - GlobeNewsWire

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of ...

NEW YORK and LONDON, July 07, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory...

4 months ago - GlobeNewsWire

Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operati...

NEW YORK and LONDON, June 13, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory...

5 months ago - GlobeNewsWire

Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society...

NEW YORK and LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory ...

6 months ago - GlobeNewsWire

Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress

NEW YORK and LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, t...

6 months ago - GlobeNewsWire

Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification o...

NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory ...

6 months ago - GlobeNewsWire

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous P...

NEW YORK and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company focused on development of advanced therapies for autoimmune and inflammat...

6 months ago - GlobeNewsWire

Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (...

NEW YORK and LONDON, May 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company focused on the development of advanced therapies for autoimmune and infla...

6 months ago - GlobeNewsWire

Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the S...

NEW YORK and LONDON, March 21, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

8 months ago - GlobeNewsWire

Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain an...

Broad-acting antihistamine has potential in number of disease areas with unmet clinical need Broad-acting antihistamine has potential in number of disease areas with unmet clinical need

8 months ago - GlobeNewsWire

Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

NEW YORK and LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan ...

8 months ago - GlobeNewsWire

Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5) Industry veteran brings extensive experi...

8 months ago - GlobeNewsWire

Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes o...

NEW YORK and LONDON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

8 months ago - GlobeNewsWire

Akari Therapeutics to Present at BIO CEO & Investor Conference

NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

9 months ago - GlobeNewsWire